SMR March 27th Options Begin Trading

The piece outlines option strategies for NuScale Power Corp. (SMR), noting the stock trades at $14.76. Selling the $12.00 put (bid $0.75) would set an effective cost basis of $11.25, ~19% below the current price, with a 78% estimated chance of expiring worthless and a 6.25% return (45.66% annualized) if it does. Selling a covered call at the $20.00 strike (bid $0.82) would yield 5.56% (40.59% annualized) to March 27 expiration with a 66% chance of expiring worthless; implied volatilities are ~116% (put) and 119% (call) versus a 12‑month trailing volatility of 106%.

Analysis

Market structure: The options market is signaling asymmetric conviction — short-dated implied vols (116–119%) exceed 1y realized (106%), pricing elevated tail risk but not panic. Winners are premium sellers and buy-and-hold investors seeking income (collecting 5–6% near-term boosts); losers are long-dated directional speculators if a sudden positive news spike forces large IV compression or assignment. Liquidity is concentrated in short expiries, so flow-driven gamma could amplify intraday moves around catalysts.

Risk assessment: Tail risks include regulatory setbacks (NRC/DOE funding cuts), dilution from equity raises, or a tech/contract failure that can halve equity value — low-probability but >30% P&L hits if triggered. Near term (days–weeks) option decay dominates P/L; medium term (months) licensing/funding news will drive repricing; long term (quarters–years) execution on reactor commercialization and cash burn determine equity value. Hidden dependencies: shallow share and option liquidity, retail gamma, and potential corporate actions (rights/dilution) that would invalidate short-put assignment plans.

Trade implications: Preferred direct plays are defined-risk income trades that harvest premium while capping downside: cash‑secured or vertical puts at $12 strike and covered calls at $20 strike to earn ~5–6% through Mar 27 (annualized ~40–46%). Avoid naked short calls; consider put spreads to limit assignment exposure. Size allocations should be tactical (1–3% portfolio per strategy) and trimmed if IV compresses >20% or SMR moves >±25%.

Contrarian angles: Consensus treats SMR as an option on commercialization; that misses binary funding/regulatory catalysts that can rerate >50% quickly. The IV premium vs realized is only modest — selling premium is arguably underdone relative to the company’s execution volatility. Conversely, if DOE/contract wins arrive, covered-call sellers risk large opportunity cost; a two‑way plan to buy back calls at $19.50 or with IV <90% avoids regret.

Key Decisions for Investors

• Sell cash‑secured SMR Mar27 $12 puts (sell-to-open) size to equal 1–2% of portfolio exposure (e.g., 1 contract per $50k AUM = 100 shares). Collect ~$0.75; target assigned basis $11.25. Risk control: buy-to-close or roll if SMR < $10 or IV compresses by >20% from current levels.
• If long SMR equity, sell Mar27 $20 covered calls to realize ~5.6% near-term premium (cap total to ~1–3% portfolio). Buy back calls if share > $19.50 or after positive regulatory/capital announcement to retain upside.
• Prefer defined‑risk put spread instead of naked puts: sell Mar27 $12 put and buy $9 put to limit downside; size to 1–2% portfolio. Maximum loss = strike width minus net credit; close/roll if SMR < $10 or IV falls >25%.
• Monitor two catalysts over 30–180 days: (1) DOE/NRC funding or contract awards — positive trigger to convert income trades to long equity; (2) any equity issuance filings — negative trigger to reduce net exposure by 50% within 5 trading days.